Kornimate/medical-research-clean huggingface dataset:
mechanical ventilation in surgical patients

Conditions: Surgery; Ventilator Lung; Postoperative Complications

Summary: this is an investigator-initiated, international, multicenter, prospective, cross-sectional study that aims to 1) describe the incidence and types of postoperative pulmonary complications (ppcs), 2) describe patient demographics, baseline characteristics, and intraoperative ventilation management, 3) describe the occurrence of intraoperative adverse events (iaes), and 4) their associations with ppcs, 5) assess the practice of intraoperative mechanical ventilation. patients will be eligible for participation if: 1) adult and 2) receiving intraoperative ventilation during general anesthesia for surgery. patients receiving ventilation outside of an operating room as well as patients receiving intraoperative ventilation during extracorporeal life support will be excluded

this is an investigator-initiated, international, multicenter, prospective, cross-sectional study the here proposed study aims to 1) describe the incidence and types of postoperative pulmonary complications (ppcs), 2) describe patient demographics, baseline characteristics, and intraoperative ventilation management, 3) describe the occurrence of intraoperative adverse events (iaes), and 4) their associations with ppcs, 5) assess the practice of intraoperative mechanical ventilation. patients will be eligible for participation if: 1) adult and 2) receiving intraoperative ventilation during general anesthesia for surgery. patients receiving ventilation outside of an operating room as well as patients receiving intraoperative ventilation during extracorporeal life support will be excluded. the primary endpoint is to report the number of patients with ppcs occurring in the first 5 postoperative days. as secondary endpoint, the practice of mechanical ventilation in patients undergoing general anesthesia for surgery will be ascertained including key intraoperative ventilator characteristics and respiratory system mechanics. other secondary endpoints will include: incidence and type of iaes; postoperative complications other than ppcs in the first 5 postoperative days; intensive care unit (icu) admission and length of stay, hospital length of stay, and hospital mortality on day 28. participating hospitals have the flexibility to choose a specific time period for data collection, but it is imperative that this process occurs within 8 weeks from receiving approval by the local ethics committee. furthermore, each participating center will conduct data collection during a predetermined 7-day period. local investigators will capture data in an electronic case recording form, including patient demographics and baseline characteristics, intraoperative ventilator settings and ventilation parameters, and outcomes.

Eligibility criteria:
inclusion criteria: * adults; and * receiving intraoperative imv (via tracheal intubation, or supraglottic device ) during general anesthesia for surgery exclusion criteria: * receiving intraoperative imv outside of an operating room; and * receiving intraoperative imv during extracorporeal life support
effect of arabinoxylan oligosaccharides consumption on insulin resistance in patients with metabolic syndrome

Conditions: Metabolic Syndrome

Summary: during this project the investigators will evaluate whether the effects of arabinoxylan oligosaccharides (axos) consumption on insulin resistance in participants with metabolic syndrome can be explained by the production of short-chain fatty acids (scfa). secondly, the investigators will evaluate whether changes in gut hormone production might explain the effect on insulin resistance.


Eligibility criteria:
inclusion criteria: * age between 18 and 65 years * regular diet (3 meals/day on at least 5 days/week) * central obese (defined as waist circumference ≥ 94cm for europid men and ≥ 80cm for europid women, with ethnicity specific values for other groups) * insulin resistant: homa-ir \> 1.7 or fasting glucose \> 100mg/dl * and one of the following three factors: * elevated tg level: ≥ 150 mg/dl (1.7 mmol/l) * decreased hdl cholesterol level: \< 40 mg/dl (1.03 mmol/l\*) in males and \< 50 mg/dl (1.29 mmol/l\*) in females * elevated blood pressure (bp): systolic bp ≥ 130 or diastolic bp ≥ 85 mm hg exclusion criteria: * low calorie diet or other special diet during the study or during the last month prior to the study * serious chronic disease of the gastrointestinal tract, such as inflammatory bowel disease (crohn's disease or ulcerative colitis), irritable bowel syndrome, chronic constipation (less than 3 bowel movements a week), chronic frequent diarrhoea (more than 3 stools a day), clinically relevant lactose intolerance, ... * use of antibiotics during the last month before starting the study * abdominal surgery in the past (except from appendectomy) * use of medication that affects the gastro-intestinal tract during the last 2 weeks prior to the study including spasmolytics, anti-diarrhoea medication, anti-constipation medication, and/or pre- or probiotic supplements (e.g. lacteol, enterol) * pregnancy, pregnancy desire or lactation * diabetes (type 1 or 2), i.e. hba1c \> 6.5 % * abnormal haemoglobin (hb) levels in blood, men must have an hb level between 14.0 and 18.0 g / dl and women between 12.0 and 16.0 g / dl.
effect of dexmedetomidine preconditioning on myocardial ischemia-reperfusion injury in patients undergoing open heart surgery with cardiopulmonary bypass

Conditions: Ischemia-Reperfusion Injury

Summary: about 200000 cardiac operations are performed in china every year. cardiopulmonary bypass is the basic strategy of open-heart surgery, which may lead to myocardial ischemia-reperfusion injury and low cardiac output syndrome. it will inevitably affect the patient's postoperative recovery. a number of studies have shown that dexmedetomidine, as an auxiliary sedative, has the effects of inhibiting stress response, antiarrhythmia and cardiac protection.dexmedetomidine has been widely used in anesthesia in cardiac surgery. however, at present, few clinical studies pay attention to its mechanism. in this study, dexmedetomidine will be used in cardiac surgery with cardiopulmonary bypass to explore the mechanism of cardiac ischemia-reperfusion injury and the protective effect of dexmedetomidine.


Eligibility criteria:
inclusion criteria: 1. aged 18-70 years 2. american society of anesthesiologists(asa) physical status of i-ⅳ 3. bmi: 18.5-28 kg/m2 4. type of operation: elective open-heart surgery with cardiopulmonary bypass 5. the patient and/or family members have signed the informed consent. exclusion criteria: 1. preoperative diagnosis of heart failure 、gradeⅱ-ⅲ heart block and diabetes 2. levf\<40% 3. severe coagulation dysfunction 4. severe heart, lung, liver and kidney insufficiency 5. used to have immunosuppressive therapies such as radiotherapy, chemotherapy and glucocorticoid, or have immune system diseases 6. perioperative allogeneic blood transfusion
early fdg pet in melanoma

Conditions: Clinical Stage III Nodal or Intransit Disease or Resectable Stage IV Melanoma

Summary: adult patients with histologically proven melanoma who will be treated with pembrolizumab will undergo fdg pet/ct scan as an early evaluation of response to therapy. changes in fdg uptake will be correlated with lab and pathology results.


Eligibility criteria:
inclusion criteria: * adult patients, at least 18 years of age * history of histologically confirmed melanoma as assessed per medical record review. * eligible for the trial upcc #01615, "a phase ib tissue collection study of pembrolizumab (mk-3475) in subjects with resectable advanced melanoma." * participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures. exclusion criteria: * females who are pregnant or breast-feeding at the time of screening will not be eligible for this study. female participants of child-bearing potential will have a urine or serum pregnancy test at the time of the screening visit. * inability to tolerate imaging procedures in the opinion of the investigator or treating physician. * serious or unstable medical or psychological conditions that, in the opinion of the investigator would compromise the subject's safety or successful participation in the study. * ineligible for the trial upcc #01615, "a phase ib tissue collection study of pembrolizumab (mk-3475) in subjects with resectable advanced melanoma." * only individuals (aged 18 or over) who can understand and give informed consent will be eligible to participate in this study. individuals who are considered to be mentally disabled will not be recruited for this study. all subjects must be able to give informed consent. we will not be using specific methods to assess decisional capacity. economically disadvantaged persons will not be vulnerable to undue influence, as this study offers no compensation. all individuals will be told that their choice regarding study participation will in no way change their access to clinical care. this should negate any undue influence or coercion. children, fetuses, neonates, or prisoners are not included in this research study.
comparison of 30% metformin and 2% nicotinamide lotion with kligman formula in the treatment of melasma

Conditions: Melasma

Summary: comparison of 30% metformin and 2% nicotinamide lotion with kligman formula in the treatment of melasma

a comparative study to evaluate efficacy and tolerability of new lotion in the treatment of melasma.

Eligibility criteria:
inclusion criteria: * age between 18-50 * no systemic therapy * all co-morbids exclusion criteria: * pregnancy * age \>50 * taking oral treatment for melasma
om and trauma study

Conditions: PTSD

Summary: the primary purpose of this study is to use an unblinded, uncontrolled, 1-month interventional single group pilot study, to assess the possibility of orgasmic meditation practice being used as a possible intervention for ptsd. the secondary purpose of this study is to examine if om is associated with a decrease in the symptoms and self-assessed experiences associated with trauma. the om trauma protocol (omtp) is designed to systematize the application of orgasmic meditation (om) for individuals seeking relief from a wide variety of problems and/or help them in their pursuit of eudaimonia. the study protocol will evaluate whether oming (the act of practicing om) shows potential for being an effective intervention for people suffering from post-traumatic stress disorder (ptsd).


Eligibility criteria:
inclusion criteria: * adults ≥18 years old * one or more participants of the pair having a diagnosis of ptsd for \> 6 months * relationship for \> 6 months * self or partner of female sex * massachusetts residents * access and ability to use internet and a video platform called zoom * no history of doing the practice of om exclusion criteria: * ongoing or active use of illicit drugs at the time of the study * self-identify as pregnant * inability to speak english * recent hospitalization \< 12 months * suicidal ideation \< 12 months * self-harm \< 12 months
clinical relevance of the reverse lipopolysaccharide transport pathway in patients with acute peritonitis

Conditions: Peritonitis

Summary: when there is infection in the intra-abdominal area, bacteria secrete toxins that are absorbed by the peritoneum. these toxins then bind to lipoproteins (which carry cholesterol in the blood) and are eliminated by the liver. phospholipid transfer protein (pltp) is a protein that facilitates the binding of bacterial toxins to lipoproteins and thus their elimination. the objective of this study is to study the relationship between pltp and the elimination of bacterial toxins in humans. a better understanding of the elimination of these toxins will lead to a better understanding of the disease. the ultimate objective is to improve the management of intra-abdominal infections.


Eligibility criteria:
inclusion criteria: * person who has given oral consent (patient or family member) * pre-operative sepsis criteria (qsofa \>=2) or vasopressor or mechanical ventilation treatment * admitted to the operating room for suspected generalized secondary peritonitis exclusion criteria: * person not affiliated to national health insurance * person under legal protection (curatorship, guardianship) * person under court order * pregnant, parturient or breastfeeding woman * minor * immunosuppression (hiv infection, corticosteroid treatment \> 0.15 mg/kg/day prednisolone equivalent \> 2 weeks, immunosuppressive treatment, primary cellular immune deficiency) * decision to limit or stop therapy
tongue morphology and posterior airway space as predictors of response in patientswith hypoglossal nerve stimulation therapy

Conditions: Obstructive Sleep Apnea; Sleep-Disordered Breathing

Summary: hypoglossal nerve stimulation (hns) plays an increasingly important role in managing patients with obstructive sleep apnea (osa) who do not tolerate cpap therapy and are not eligible for other alternative treatment options, such as mandibular advancement devices or positional therapy. the posterior upper airway space dimensions are crucial in managing patients with hns in the patient selection process and therapy control. the lateral collapse of the upper airway is of crucial importance. lateral collapse at the palatal level and of the oropharyngeal walls is a well-established negative predictive factor for therapeutic success. patients with complete concentric collapse at the palatal level (pccc) in drug-induced sedation endoscopy (dise) must be excluded from the implantation of hns, which is cumbersome and invasive. endoscopy has the inherent limitation that only one level can be observed at a given time, and assessment is possibly hampered by phlegm. during activation and titration of hns, tongue protrusion is observed in the awake patient. however, this method does not allow for assessing the opening of the retroglossal (rg) and retropalatal (rp) airway space, which is the ultimate therapeutic goal. insufficient opening of the airway is the reason for non-responders with hns. insufficient upper airway opening can be either at the retropalatal or retroglossal level. the study aims to identify insufficient airway openings better using sub-mental ultrasonography. sub-mental standardized and orientated ultrasonography offers a quantitative, reproducible way of assessing transverse upper airway dimensions and anatomic features of the upper airway in a rapid and non-invasive manner. in addition, anatomic characteristics of the airway's adjacent tissue, such as the size and shape of the tongue, may also have an impact on the effectiveness of hns. tongue morphology and posterior airway space assessment could be used in preoperative evaluation and during therapeutic titration of hns. the clinical routine could be included tongue morphology and posterior airway space assessment without additional patient risks. however, the clinical value of assessing posterior airway space and tongue morphology in patients with hns is yet unknown.


Eligibility criteria:
inclusion criteria: * patients older than 18 year * patients with a hypoglossal nerve implantation * control group: 15 subjects without osa (ahi\<10/h) * written informed consent * sufficient knowledge of german or french to understand informed consent exclusion criteria: * patients younger than 18 years * unwillingness to give informed consent * incapable of performing müller's maneuver * history of head and neck surgery other than hns, tonsillectomy, and maxillomandibular advancement * diagnosis of congestive heart failure or chronic pulmonary disease * diagnosis of co-morbid sleep disorders, including central sleep apnea * pregnancy

Keywords: hypoglossal nerve stimulation ultrasonography
metabolomic analysis of systemic sclerosis

Conditions: Scleroderma (Limited and Diffuse); Undifferentiated Connective Tissue Disease; Raynaud Disease; Vascular Disease; Healthy Control Subjects

Summary: currently investigators do not have diagnostic and prognostic markers for ssc which almost always starts with a vascular disease (raynaud's disease) isolated for several years. the primary purpose is to highlight discriminating metabolic profiles depending on the characteristics of the disease, allowing early diagnosis of ssc at the onset of vascular lesions, by comparing the profiles of ssc beginners (\ 3 years). secondary purposes: * prognosis: to study the metabolomics profile of ssc when a visceral complication occurs * diagnosis: to compare the metabolomics profile of ssc to undifferentiated connective tissue disease (ucdt), raynaud's disease (rd), vascular disease (vd) and healthy controls * exploratory: to compare the metabolomics profile of blood, urine and skin of ssc patients


Eligibility criteria:
inclusion criteria: * group 1 (scleroderma) : patients with acr / eular (2012) and / or criteria of leroy and medsger (2001) * group 2 (ucdt) : patients with criteria proposed by mosca et al. (1998) * group 3 (raynaud) : patients with primary and isolated raynaud disease * group 4 (vascular disease) : patients with type 2 diabetes, occlusive vascular disease, history of myocardial infarction or ischemic stroke * group 5 (healthy control) : healthy subjects (no sign of connective tissue disease, no raynaud, no vascular disease) exclusion criteria: * group 1 (scleroderma) : patients not fulfilling acr / eular (2012) and / or criteria of leroy and medsger (2001), or with another auto-immune disease * group 2 (ucdt) : patients not fulfilling criteria proposed by mosca et al. (1998) * group 3 (raynaud) : patients with no raynaud disease * group 4 (vascular disease) : patients with no vascular disease * group 5 (healthy control) : patients with sign of connective tissue disease, raynaud, or vascular disease)
efficacy and safety of tadalafil in hemodialysis patients

Conditions: Erectile Dysfunction

Summary: the purpose of this study is to check the safety and efficacy of a pde5 inhibitor, tadalafil, is a special group of patients: renal chronic patients in hemodialysis treatment.

in our country, the number of patients in hemodialysis for the treatment of renal chronic dysfunction is very huge. as we know this group has a greater prevalence of sexual dysfunction than the general population, and among these dysfunctions erectile disfunction(ed) occupies maybe the most important position. with the advent of the increase aging of the nation´s population and the small number of organ donations, the number of men suffering from ed in hemodialysis surely will be very significant causing a very important problem for our health system. up to now there´s little indexed publications supporting the use of tadalafil in this special group of men. another pde 5 inhibitor, sildenafil, was used in this patients with success and safety but obviously we need other options with the same efficacy. we intend this study to give us more background to treat ed in this already unfortunate ones.

Eligibility criteria:
inclusion criteria: * men between 18 and 70 years old * diagnosticated ed for 6 months at least * accept the protocol * sign the informed consent * renal chronic patients in hemodyalisis exclusion criteria: * history of another pde5 inhibittor use. * c.c.i. grade iii (nyha)

Keywords: erectile dysfunction chronic renal dysfunction tadalafil
sleep health education and social support among blacks with osa

Conditions: Obstructive Sleep Apnea

Summary: the primary purpose of this study is to ascertain the effectiveness of tailored, peer based sleep health education and social support in increasing adherence rates to recommended obstructive sleep apnea (osa) evaluation and treatment among blacks at risk of obstructive sleep apnea.

obstructive sleep apnea (osa), which disproportionately affects blacks (31% vs. 10%, whites), is a critical, preventable and/or treatable disease potentially causing increased cardiovascular disease (cvd) outcomes (e.g., obesity, diabetes, hypertension, stroke, arrhythmia, and chronic heart failure). improving sleep may have direct effects in reducing cvd risk,2 enhancing brain functions, and increasing workplace productivity. unfortunately, our focus groups suggest that most at-risk blacks are unaware of osa symptoms or its related morbidity. thus, it is imperative to address poor adherence among blacks with osa, if we are to reduce health disparities associated with cvd outcomes between blacks and whites. this is a randomized study with a total of 6 sites recruiting; 3 will serve as controls and 3 that will be intervention. group a participants (intervention group) will receive health education from a trained peer health educator and group b participants (control group) will meet with a salon worker, barbershop worker, or church health ministry group leader. participants will be asked to use a sleep diary and wear a home sleep test device to measure sleep for 7 days. they will be followed for 12 months.

Eligibility criteria:
inclusion criteria: * self-reported race/ethnic minority * ages ≥18 years * accessible by telephone * consent to participate, which includes permission to release medical record information * a positive screening for osa is necessary to be enrolled in the intervention protocol. exclusion criteria: * are involved in another sleep study. * are unable to understand and sign this informed consent form. * know someone who is participating in this study. * had a heart attack or stroke within the past 12 weeks. * do not identify yourself as a racial/ethnic minority. * are pregnant. * refuse to use the arestm home sleep test device. * refuse to use the watchpattm home sleep test device. * are not at risk for sleep apnea.
daily disposable comparison study

Conditions: Myopia

Summary: the objective of the study is to compare the overall subjective preference between two daily disposable hydrogel lenses when refitted into a third hydrogel lens.

this was a two-day, randomized, non-dispensing, double-masked, contralateral study with two parallel groups. participants were recruited into one of two groups - participants who habitually wore etafilcon a lens and participants who habitually wore nelfilcon a lens.

Eligibility criteria:
inclusion criteria: 1. is at least 17 years of age and has full legal capacity to volunteer; 2. has read and signed an information consent letter; 3. is willing and able to follow instructions and maintain the appointment schedule; 4. is correctable to a visual acuity of 20/40 or better (in each eye) with their habitual correction and the assigned study lenses; 5. habitually wears either 1 day acuvue moist or dailies aqua comfort plus contact lenses. 6. demonstrates an acceptable fit with the study lenses exclusion criteria: 1. is participating in any concurrent clinical or research study; 2. has any known active\* ocular disease and/or infection; 3. has a systemic condition that in the opinion of the investigator may affect a study outcome variable; 4. is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable; 5. has known sensitivity to the diagnostic pharmaceuticals to be used in the study; 6. is pregnant, lactating or planning a pregnancy at the time of enrolment (by verbal confirmation at the screening visit); 7. is aphakic; 8. has undergone refractive error surgery;